EDSA vs IMVT

Analysts rate Edesa Biotech, Inc.

(EDSA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +207. 0%, compared to -86. 2% for Edesa Biotech, Inc. (EDSA). Over 10 years, the gap is even starker: IMVT returned +230. 5% versus EDSA's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edesa Biotech, Inc.

(EDSA) is the lower-risk stock at -0. 29β versus Immunovant, Inc. 's 1. 67β — meaning IMVT is approximately -686% more volatile than EDSA relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Edesa Biotech, Inc.

grew EPS 34. 2% year-over-year, compared to -1. 5% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edesa Biotech, Inc.

(EDSA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EDSA leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — EDSA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Edesa Biotech, Inc.

(EDSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 29)). Immunovant, Inc. (IMVT) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EDSA: -99. 3%, IMVT: +230. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.